Forte Biosciences (FBRX) Debt to Equity (2016 - 2019)
Forte Biosciences (FBRX) has disclosed Debt to Equity for 4 consecutive years, with -$8.67 as the latest value for Q2 2019.
- Quarterly Debt to Equity fell 1641.2% to -$8.67 in Q2 2019 from the year-ago period, while the trailing twelve-month figure was -$8.67 through Jun 2019, down 1641.2% year-over-year, with the annual reading at -$35.6 for FY2018, 69905.83% down from the prior year.
- Debt to Equity for Q2 2019 was -$8.67 at Forte Biosciences, up from -$12.58 in the prior quarter.
- The five-year high for Debt to Equity was $0.56 in Q2 2018, with the low at -$35.6 in Q4 2018.
- Average Debt to Equity over 4 years is -$5.06, with a median of $0.03 recorded in 2018.
- Peak annual rise in Debt to Equity hit 730.04% in 2018, while the deepest fall reached 69905.83% in 2018.
- Over 4 years, Debt to Equity stood at -$0.08 in 2016, then soared by 161.96% to $0.05 in 2017, then crashed by 69905.83% to -$35.6 in 2018, then soared by 75.66% to -$8.67 in 2019.
- According to Business Quant data, Debt to Equity over the past three periods came in at -$8.67, -$12.58, and -$35.6 for Q2 2019, Q1 2019, and Q4 2018 respectively.